Actively Recruiting
Phase 4 Study of Prophylactic Tocilizumab to Reduce Cytokine Release Syndrome Risk in Adults with RelapsedRefractory Multiple Myeloma Treated with Linvoseltamab
Led by Regeneron Pharmaceuticals · Updated on 2026-10-27
30
Participants Needed
7
Research Sites
60 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether giving tocilizumab before the first dose of linvoseltamab can reduce the risk of Cytokine Release Syndrome CRS in adults with Relapsed or Refractory Multiple Myeloma RRMM. Participants have received at least four prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. This Phase 4 study aims to assess the safety, tolerability, and effectiveness of linvoseltamab after tocilizumab use. Participants receive linvoseltamab along with prophylactic tocilizumab administered according to the study protocol. The study is conducted in an outpatient setting and follows a single group design. Researchers monitor how tocilizumab affects CRS occurrence, severity, hospital visits related to CRS, and the need for additional medications like corticosteroids or extra tocilizumab doses. During the study, participants undergo assessments up to 28 days and up to 12 months to record CRS events, infections, neurotoxicity, neutropenia, hospitalizations, and adverse events. Efficacy outcomes such as response rates, progression-free survival, and overall survival are also tracked. Safety and treatment-emergent adverse events are monitored throughout the study duration, which extends until December 2028.
CONDITIONS
Brief Title
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here